6/3/2010

Cerephex said it will submit an application with the FDA within a year to seek 510(k) clearance for NeuroPoint, a non-invasive device that delivers cortical stimulation to treat fibromyalgia. The company plans to schedule a July meeting with the agency to ask for comments on its two-year study data.

Related Summaries